Chiglitazar in combination with anti-inflammatory and hepatoprotective therapy for the treatment of MASH associated with T2DM: a prospective, multicentre, randomised, double-blind, placebo-controlled study protocolKai He, Hui Li, Wanjun Jiang et al.|BMJ Open|2026Cited by 0